Form 4: Roivant Sciences Director, Melissa B. Epperly, Reports Acquisition of Common Shares

Melissa B. Epperly, a director of Roivant Sciences Ltd., reports acquiring 1,847 common shares as part of the company's Non-Employee Director Compensation Plan.

Summary

• On April 17, 2025, Melissa B. Epperly, a director of Roivant Sciences Ltd., acquired 1,847 common shares.
• The shares were awarded pursuant to the Issuer's Non-Employee Director Compensation Plan and were fully vested as of the grant date.
• The transaction resulted in Ms. Epperly beneficially owning 41,376 common shares following the reported transaction.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director demonstrates alignment with the company's success.
• The shares were awarded as part of a compensation plan, indicating a structured approach to director compensation.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as part of compensation packages to align director interests with shareholder value.

Comparison to Industry Standards

• Director compensation packages often include stock options or restricted stock units that vest over time.
• The number of shares awarded to Ms. Epperly is within the typical range for non-employee director compensation plans in comparable pharmaceutical companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Roivant Sciences, Director Compensation, Common Shares, Beneficial Ownership, Form 4, Epperly, Acquisition